Glioblastoma is the most common malignant brain tumor, responsible for roughly half of all malignant primary brain tumors worldwide. When time matters, the proven standard is glioblastoma radiotherapy temozolomide—a paired approach that increases survival compared to radiation alone. This page condenses what patients and families need to know and shows how leading Bangalore oncologist Dr. Mathangi J personalizes care for better outcomes.
Quick answer (30-second summary)
- What is it? A combination of focused radiotherapy with the oral drug temozolomide given together (and then in cycles) after surgery.
- Why it matters? This combined glioblastoma therapy extends survival and improves tumor control versus radiation alone.
- Who is it for? Most fit adults after maximal safe resection; benefit is strongest when the tumor’s MGMT gene promoter is methylated.
Fact 1: What is the combined approach and how does it work?
Chemotherapy with radiotherapy means giving daily temozolomide while you receive focused radiation to the tumor bed and surrounding margin. Radiation damages cancer DNA; temozolomide interferes with DNA repair inside the tumor, making each radiation fraction more lethal. This synergy is why concurrent chemoradiotherapy is the backbone of modern glioblastoma care.
In practice, your neuro-oncology team plans a conformal radiation course and coordinates drug timing so peaks of drug activity overlap with radiation exposure—an elegant example of effective oncology combination therapy.
Fact 2: How much survival benefit does the combination add?
The landmark randomized trial that established the standard demonstrated a clear survival advantage for radiotherapy plus temozolomide versus radiotherapy alone. For older adults who cannot tolerate a long course, a validated short-course regimen plus temozolomide also improves outcomes.
| Regimen | Median overall survival | Two-year survival | Key notes |
|---|---|---|---|
| Standard RT (60 Gy/30 fractions) + temozolomide | ~14.6 months | ~26.5% | Improved over RT alone (~12.1 months; ~10.4% at 2 years) |
| Short-course RT (40 Gy/15) + temozolomide (elderly) | ~9.3 months | — | Improved over short-course RT alone (~7.6 months) |
Numbers shown are rounded for readability and come from pivotal randomized trials in newly diagnosed glioblastoma.
Fact 3: What is the temozolomide protocol and dosing rhythm?
The typical temozolomide protocol has two phases:
- Concurrent phase: Oral temozolomide is taken daily at a low dose while radiotherapy is delivered (usually 6–7 weeks). Your team will also prescribe Pneumocystis pneumonia prophylaxis and monitor counts.
- Adjuvant phase: After a short break, temozolomide continues in monthly cycles—higher dose for 5 days, then 23 days off—for at least 6 cycles when tolerated.
Precise dosing depends on blood counts, healing after surgery, and overall fitness. This cadence keeps pressure on microscopic disease while your brain recovers from surgery and radiation.
Fact 4: Who benefits most from the combination?
All eligible adults generally benefit from combination therapy, but patients whose tumors have MGMT promoter methylation experience the greatest gain because their cells repair chemotherapy damage less efficiently. Age, performance status, and extent of resection also influence the plan. In older or frail patients, short-course radiation plus temozolomide balances effectiveness and tolerance.
Fact 5: Which brain tumor treatment drugs matter in this setting?
Among brain tumor treatment drugs, temozolomide is pivotal because it reaches the brain, is taken orally, and synergizes with radiation. For selected cases, additional agents may be considered in trials or at recurrence. The evidence base continues to expand, but for frontline care, glioblastoma drug treatment anchored by temozolomide with precise radiotherapy remains the most widely validated path.
Fact 6: Why precision radiotherapy at Gleneagles improves confidence
Technique matters. Under Dr. Mathangi J—Senior Consultant & In-charge of Radiation Oncology and Director of Fellowship in Advanced Radiotherapy techniques—planning leverages IGRT, Gated RapidArc, DIBH strategies when applicable, and the Asia-Pacific’s first TrueBeam STx installation. This precision limits dose to healthy tissue and keeps your cognitive function top-of-mind while delivering powerful, conformal treatment.
- Image guidance verifies position every session.
- Modern planning algorithms shape dose to complex brain anatomy.
- Adaptive decisions fine-tune margins if the post-operative cavity changes.
Fact 7: What side effects should you expect and how are they managed?
Most patients complete the combined course successfully. Common effects include fatigue, scalp irritation, transient hair loss in the radiation field, and blood-count suppression from chemotherapy. Grade 3/4 hematologic events are uncommon with careful monitoring. Your team will schedule weekly labs during the concurrent phase, provide anti-nausea medicines, and adjust doses as needed.
How Dr. Mathangi personalizes oncology combination therapy
Every plan starts with maximally safe surgery, then oncology combination therapy tuned to pathology and performance status. Dr. Mathangi draws on 20+ years of experience, international training (Germany & Denmark), and 12,000+ successfully treated patients to individualize contouring, margins, and dose constraints—details that add up to better tolerance and control.
Centres of expertise: Brain, head & neck, lung, breast, cervix, endometrium, prostate, liver, bladder, esophagus, rectum, spine, anal canal, vulva, and penile cancers.
How this approach fits into your journey
What happens first?
Post-operative MRI guides target volumes. Dental and skin checks reduce treatment breaks. You’ll start the concurrent phase once surgical healing is secure.
What does a typical week look like?
- Weekdays: 1 brief radiotherapy session (usually under 15 minutes on the couch).
- Daily: Oral temozolomide at home during the concurrent phase.
- Weekly: Blood counts and toxicity review; dose adjustments if required.
What about after the combined phase?
Imaging at 4–6 weeks provides a new baseline, then adjuvant temozolomide cycles continue with MRI every 2–3 months. If progression occurs, options include re-surgery, re-irradiation in select cases, or trials—always discussed in a multidisciplinary board.
Why patients across India choose Dr. Mathangi for concurrent chemoradiotherapy
- Leadership & training: Fellowship director in advanced radiotherapy; trained in SRS/SBRT (Germany) and IGRT/RapidArc (Denmark).
- Technology: Access to TrueBeam STx and modern planning suites for exacting brain work.
- Experience: Over 12,000 patients treated with consistently high standards of safety and compassion.
- Continuity: From simulation to survivorship, one accountable team led by your consultant.
Where do the key terms fit into your plan?
Patients often read different phrases for the same strategy. In your plan, combined glioblastoma therapy and concurrent chemoradiotherapy both refer to radiotherapy plus temozolomide given together, followed by cycles of temozolomide. Temozolomide is central to glioblastoma drug treatment and remains one of the most proven brain tumor treatment drugs today. All of these are delivered within a structured temozolomide protocol as part of an evidence-based oncology combination therapy.
